The company has entered into a distribution agreement with Qualia Pharma for marketing and sales of ColdZyme Mouth Spray on the Greek and Cypriot market.
The background to the agreement is that Qualia Pharma acquired Life NLB on March 1, 2018. The distribution agreement that Enzymatica previously had with Life NLB is now being transferred to Qualia Pharma.
“We see a clear advantage to signing an agreement with Qualia Pharma, which is a larger market participant and can conduct a stronger marketing campaign for ColdZyme in Greece and on Cyprus,” says Fredrik Lindberg, CEO of Enzymatica.
The Greek and Cypriot cold products market, which is estimated to be worth SEK 670 million, is a stable market. ColdZyme began to be sold to pharmacies in both markets in 2017. In 2018 a launch was initiated targeting consumers, pharmacists and healthcare personnel.
